BCM
CRMD icon

Bayesian Capital Management’s CorMedix CRMD Stock Holding History

Bayesian Capital Management’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,519
Closed -$39.6K – 832
2023
Q4 		$39.6K Buy
+10,519
New +$36.2K ﹤0.01% 682

Other funds holding CRMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bayesian Capital Management's CRMD Position: Q1 2024 in Review

Bayesian Capital Management sold out of CorMedix (CRMD) in Q1 2024, closing a stake of 10,519 shares — an estimated $39.6K sold.

Bayesian Capital Management first reported a position in CRMD in Q4 2023 and held it in 1 quarter. The position peaked at $39.6K in Q4 2023. 91 funds tracked by Wall St. Rank hold CRMD as of Q1 2024.

  • Bayesian Capital Management reported no remaining CorMedix position as of Q1 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 10,519 CorMedix shares in Q1 2024, an estimated $39.6K.
  • Bayesian Capital Management first reported a position in CorMedix in Q4 2023 and held it in 1 quarter.
  • Bayesian Capital Management's CorMedix position peaked at $39.6K in Q4 2023.
  • 91 funds tracked by Wall St. Rank held CorMedix as of Q1 2024.

Based on Bayesian Capital Management's 13F filing for Q1 2024, filed 15 May 2024.